TScan Therapeutics Closes Series B Round

TScan Therapeutics today announced the completion of its Series B raise with the inclusion of Novartis Institutes for BioMedical Research (NIBR), Pitango Venture Capital, and Astellas Venture Management (the wholly-owned venture capital organization of Astellas Pharma Inc). In addition, Series B investors include 6 Dimensions Capital, Longwood Fund, Bessemer Venture Partners, GV, and Novartis Venture Fund.

"We welcome Astellas Venture Management, Pitango and NIBR as new TScan investors into our Series B," said David P. Southwell, President and Chief Executive Officer, TScan. "They join the Series A investors 6 Dimensions, Longwood Fund (our founding investor), Google Ventures, Bessemer, and Novartis Venture Fund. With this round, TScan has raised approximately $60 million in funding and is well positioned to discover novel targets of tumor reactive T-cell receptors (TCRs), and to develop these pairs in both liquid and solid tumor indications in oncology."

About TScan Therapeutics
TScan designs therapies that reprogram a patient's own T cells to recognize and fight their cancer using naturally-occurring TCRs that find and destroy shared cancer targets. The TScan technology process allows TCRs to be scanned against target antigens in a genome-wide, high-throughput, and unbiased fashion. TScan is developing a portfolio of TCR therapies for patients suffering from both liquid and solid tumors, and has already discovered, through this process, novel antigens from TCRs, novel TCRs from known antigens, and previously uncharacterized off-targets of known TCRs.